Kunwar Shailubhai – Baruch S. Blumberg Institute

Career Experience

Founder & Chief Executive Officer, Nous Biosciences, Inc. (2022-current)
Senior Advisor and Professor (2004-Current; Joint appointment) Baruch S. Blumberg Institute and PA Biotechnology Center, Doylestown, PA 18902, USA
CEO & CSO (May 25, 2017, to August 2021) Tiziana Life Sciences (LON: TILS and NASDAQ: TLSA), Philadelphia & New York City, USA, and London, UK
Co-founder, EVP, and CSO (May 2000 to May 2017) Synergy Pharmaceuticals (NASDAQ: SYGP), Philadelphia and New York, USA
Group Leader: Cancer Group, March 1993 to October 1999 Monsanto Company (G. D. Searle & Co), St. Louis, USA

Kunwar Shailubhai, PhD, MBA

Professor

Summary

An experienced executive (Co-founder, CEO & CSO) & a scientist with 30+ years of R&D experience with successful record of ‘Bench to Market’ in startup Biotechnology and pharma companies.
Successfully advanced two start-up biotech companies to NASDAQ listing (TLSA & SGYP). These endeavors required establishing R&D pipeline, in-licensing assets, developing strong intellectual property, directing non-clinical and clinical development, developing relationships with investment firms, research analysts & KOL, and then successfully completing financings needed for IPO.
Former member of Board of a few publicly listed biotechnology companies (Symbols: SGYP, TLSA & RSNA). Currently, member of board of directors of Ampeptec, Inc., a startup biotechnology company
Scientific hands-on research experience in Inflammation, Oncology, Neurodegenerative, Infectious and Autoimmune Diseases. Conducted several clinical trials (Phase 1 and Phase 2). 50+ US Patents
Pioneer of therapeutic applications of Guanylate cyclase-C agonists (GCRA). Invented plecanatide (TRULANCE®) and directed teams from preclinical discovery, non-clinical & clinical development to FDA approval for two indications (CIC and IBS-c).
Invented dolcanatide, a GCRA, and successfully completed Phase1, phase 1b trial in ulcerative colitis and a phase 2a clinical trial in opioid-induced constipation.
Invented, developed, and patented innovative technology to enhance the success of CAR-T/CAR-NK for cancer treatment. Successfully out licensed the technology and negotiated a long-term multi-million commercial agreement with Precision Biosciences (NASDAQ: DTIL).
Invented ‘Revolutionary Technologies’ for monoclonal antibody therapeutics with alternative routes of administration for Crohn’s Disease (oral administration), neurodegenerative diseases and brain cancer (nasal route) and lung diseases (inhalation route). One patent has already been granted and several other patent applications are pending. Nasal administration technology is successfully validated by two clinical studies in multiple sclerosis and COVID-19. A phase 2 trial with oral administration for treatment of Crohn’s disease is ongoing.
Attended national and international conferences (JP Morgan, BIO, Jeffreys, Cowan’s, LT Micro, and BIO Europe) with one-on-one meetings with investors/investment firms. Traveled extensively in EU, Asia, and US for financing-related activities and to develop relationships with investment firms.